Therefore, anti-PD-L1 affibody-based immuno-PET holds great potential for noninvasive stratification of GBM patients and optimisation of PD-1/PD-L1 checkpoint blockade therapy, offering a viable remedy to the drawbacks of conventional techniques such as biopsy and IHC staining. This evidence concerns the gene PDCD1 and glioblastoma.